BOUT vs. IVOG
BOUT (Innovator IBD Breakout Opportunities ETF) and IVOG (Vanguard S&P Mid-Cap 400 Growth ETF) are both Mid Cap Growth Equities funds - BOUT tracks the IBD Breakout Stocks Total Return Index while IVOG tracks the S&P MidCap 400 Growth Index. Both are passively managed. Over the past 5 years, BOUT returned 7.49%/yr vs 8.21%/yr for IVOG. A 0.77 correlation means they provide meaningful diversification when combined. BOUT charges 0.80%/yr vs 0.10%/yr for IVOG.
Performance
BOUT vs. IVOG - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, BOUT achieves a 27.17% return, which is significantly higher than IVOG's 16.96% return.
BOUT
- 1D
- -1.06%
- 1M
- -2.85%
- 6M
- 19.86%
- YTD
- 27.17%
- 1Y
- 27.33%
- 3Y*
- 13.21%
- 5Y*
- 7.49%
- 10Y*
- —
IVOG
- 1D
- -1.05%
- 1M
- -1.65%
- 6M
- 11.10%
- YTD
- 16.96%
- 1Y
- 23.29%
- 3Y*
- 14.86%
- 5Y*
- 8.21%
- 10Y*
- 11.06%
BOUT vs. IVOG - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|---|
BOUT Innovator IBD Breakout Opportunities ETF | 27.17% | -6.77% | 18.82% | 13.27% | -22.60% | 22.69% | 50.56% | 20.59% | -30.42% |
IVOG Vanguard S&P Mid-Cap 400 Growth ETF | 16.96% | 7.34% | 15.62% | 17.36% | -19.08% | 18.85% | 22.60% | 26.13% | -18.64% |
Correlation
The correlation between BOUT and IVOG is 0.81, indicating a strong positive relationship between their price movements. Combining them offers limited diversification - they tend to fall together during downturns.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.81 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.82 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.80 |
Correlation (All Time) Calculated using the full available price history since Sep 13, 2018 | 0.77 |
The correlation between BOUT and IVOG has been stable across timeframes, ranging from 0.77 to 0.82 - a consistent structural relationship.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
BOUT vs. IVOG — Risk / Return Rank
BOUT
IVOG
BOUT vs. IVOG - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Innovator IBD Breakout Opportunities ETF (BOUT) and Vanguard S&P Mid-Cap 400 Growth ETF (IVOG). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| BOUT | IVOG | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.09 | ||
| Sortino ratioReturn per unit of downside risk | -0.21 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.23 | -0.02 |
| Calmar ratioReturn relative to maximum drawdown | 2.33 | 2.41 | -0.08 |
| Martin ratioReturn relative to average drawdown | 6.78 | 9.23 | -2.45 |
Loading charts...
Drawdowns
BOUT vs. IVOG - Drawdown Comparison
The maximum BOUT drawdown since its inception was -36.98%, smaller than the maximum IVOG drawdown of -39.32%. Use the drawdown chart below to compare losses from any high point for BOUT and IVOG.
Loading charts...
Drawdown Indicators
| BOUT | IVOG | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -36.98% | -39.32% | +2.34% |
Max Drawdown (1Y)Largest decline over 1 year | -11.76% | -9.69% | -2.07% |
Max Drawdown (3Y)Largest decline over 3 years | -25.31% | -25.61% | +0.30% |
Max Drawdown (5Y)Largest decline over 5 years | -28.28% | -29.31% | +1.03% |
Max Drawdown (10Y)Largest decline over 10 years | — | -39.32% | — |
Current DrawdownCurrent decline from peak | -5.64% | -3.90% | -1.74% |
Average DrawdownAverage peak-to-trough decline | -12.23% | -5.85% | -6.38% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 4.04% | 2.53% | +1.51% |
Volatility
BOUT vs. IVOG - Volatility Comparison
Innovator IBD Breakout Opportunities ETF (BOUT) has a higher volatility of 7.62% compared to Vanguard S&P Mid-Cap 400 Growth ETF (IVOG) at 5.56%. This indicates that BOUT's price experiences larger fluctuations and is considered to be riskier than IVOG based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| BOUT | IVOG | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 7.62% | 5.56% | +2.06% |
Volatility (6M)Calculated over the trailing 6-month period | 17.74% | 13.92% | +3.82% |
Volatility (1Y)Calculated over the trailing 1-year period | 22.51% | 17.90% | +4.61% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 19.82% | 20.72% | -0.90% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 23.01% | 20.59% | +2.42% |
BOUT vs. IVOG - Expense Ratio Comparison
BOUT has a 0.80% expense ratio, which is higher than IVOG's 0.10% expense ratio.
Dividends
BOUT vs. IVOG - Dividend Comparison
BOUT's dividend yield for the trailing twelve months is around 0.27%, less than IVOG's 0.55% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
BOUT Innovator IBD Breakout Opportunities ETF | 0.27% | 0.34% | 0.60% | 1.32% | 1.35% | 0.00% | 0.00% | 0.00% | 0.22% | 0.00% | 0.00% | 0.00% |
IVOG Vanguard S&P Mid-Cap 400 Growth ETF | 0.55% | 0.64% | 0.79% | 1.15% | 1.05% | 0.47% | 0.74% | 1.17% | 1.01% | 0.93% | 1.11% | 1.04% |
Frequently Asked Questions
BOUT and IVOG have a correlation of 0.81, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
BOUT has higher volatility (7.62%) compared to IVOG (5.56%). In terms of maximum drawdown, BOUT dropped -36.98% vs IVOG's -39.32%.
On 5-year performance, IVOG leads with 8.21% vs 7.49% for BOUT. On fees, IVOG is cheaper at 0.10% per year. On volatility, IVOG has been the lower-risk option at 5.56%. The better choice depends on whether you care most about return, fees, risk, or income.
Over the 5-year period, IVOG has performed better with a 8.21% return vs 7.49%. Past performance does not guarantee future results, so compare this with risk, fees, and fund exposure.
IVOG is cheaper with a 0.10% expense ratio, compared with 0.80% for BOUT.
IVOG has the higher dividend yield at 0.55%, compared with 0.27% for BOUT.
BOUT tracks IBD Breakout Stocks Total Return Index, while IVOG tracks S&P MidCap 400 Growth Index. They also come from different issuers: Innovator and Vanguard. Their fees differ too: 0.80% for BOUT and 0.10% for IVOG.
IVOG currently has the higher Sharpe Ratio (1.31 vs 1.22), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for BOUT and IVOG
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer